These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 21130075)

  • 1. Determining the binding mode and binding affinity constant of tyrosine kinase inhibitor PD153035 to DNA using optical tweezers.
    Cheng CM; Lee YJ; Wang WT; Hsu CT; Tsai JS; Wu CM; Ou KL; Yang TS
    Biochem Biophys Res Commun; 2011 Jan; 404(1):297-301. PubMed ID: 21130075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
    Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the zero-force binding energetics of an intercalated DNA complex by a single-molecule approach.
    Yang TS; Cui Y; Wu CM; Lo JM; Chiang CS; Shu WY; Chung WJ; Yu CS; Chiang KN; Hsu IC
    Chemphyschem; 2009 Nov; 10(16):2791-4. PubMed ID: 19795434
    [No Abstract]   [Full Text] [Related]  

  • 4. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA interaction of the tyrosine protein kinase inhibitor PD153035 and its N-methyl analogue.
    Goossens JF; Bouey-Bencteux E; Houssin R; Hénichart JP; Colson P; Houssier C; Laine W; Baldeyrou B; Bailly C
    Biochemistry; 2001 Apr; 40(15):4663-71. PubMed ID: 11294633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new strategy for the design of water-soluble synthetic receptors: specific recognition of DNA intercalators and diamines.
    Wada K; Mizutani T; Matsuoka H; Kitagawa S
    Chemistry; 2003 May; 9(10):2368-80. PubMed ID: 12772312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition on the entropic elasticity of DNA induced by intercalating molecules.
    Rocha MS; Ferreira MC; Mesquita ON
    J Chem Phys; 2007 Sep; 127(10):105108. PubMed ID: 17867787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA sequence recognition by bispyrazinonaphthalimides antitumor agents.
    Carrasco C; Joubert A; Tardy C; Maestre N; Cacho M; Braña MF; Bailly C
    Biochemistry; 2003 Oct; 42(40):11751-61. PubMed ID: 14529286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
    Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
    ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
    [No Abstract]   [Full Text] [Related]  

  • 12. Parallel contractile signal transduction pathways activated by receptors for thrombin and epidermal growth factor-urogastrone in guinea pig gastric smooth muscle: blockade by inhibitors of mitogen-activated protein kinase-kinase and phosphatidyl inositol 3'-kinase.
    Zheng XL; Renaux B; Hollenberg MD
    J Pharmacol Exp Ther; 1998 Apr; 285(1):325-34. PubMed ID: 9536028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Energetics of drug-DNA interactions.
    Chaires JB
    Biopolymers; 1997; 44(3):201-15. PubMed ID: 9591476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro.
    Samén E; Thorell JO; Fredriksson A; Stone-Elander S
    Nucl Med Biol; 2006 Nov; 33(8):1005-11. PubMed ID: 17127174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
    Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives.
    Garofalo A; Goossens L; Baldeyrou B; Lemoine A; Ravez S; Six P; David-Cordonnier MH; Bonte JP; Depreux P; Lansiaux A; Goossens JF
    J Med Chem; 2010 Nov; 53(22):8089-103. PubMed ID: 21033670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acenaphtho[1,2-b]pyrrole derivatives as new family of intercalators: various DNA binding geometry and interesting antitumor capacity.
    Zhang Z; Yang Y; Zhang D; Wang Y; Qian X; Liu F
    Bioorg Med Chem; 2006 Oct; 14(20):6962-70. PubMed ID: 16828559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.